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Abstract
Corticotropin-releasing factor-binding protein (CRF-BP) is known to regulate the bioavailability of
CRF and may also play a role in stress behaviours. CRF-BP has been localized in the pituitary as
well as central nervous system (CNS) limbic and cortical areas, including the amygdala. The signal
transduction pathways which regulate amygdalar CRF-BP are not well understood. In this report, we
have examined the effect of protein kinase A and C activators, CRF, dexamethasone and
interleukin-6 (IL6) on CRF-BP mRNA and protein expression in dissociated fetal amygdalar cultures.
CRF-BP mRNA levels were determined by Northern analysis following 12 h treatment with the
following agents: forskolin (1–30 mM), CRF (1–1000 nM), phorbol-12-myristate-13-acetate (TPA;
1–50 nM), dexamethasone (1–100 nM) and IL6 (10–500 pM). Significant increases in CRF-BP mRNA
were observed in response to forskolin (30 mM), CRF (100, 1000 nM), IL6 (100, 500 pM), TPA (50 nM)
and dexamethasone (100 nM; P<0.05 for all; n=3–6 for all). We extended our observations of
CRF-BP expression to the protein level by performing semiquantitative Western analysis of total
cellular protein after treatment with the same agents. Twenty-four hour treatment with 30 mM
forskolin, 1000 nM CRF, 50 nM TPA, 100 pM IL6 or 100 nM dexamethasone significantly increased
CRF-BP expression (P<0.05, n=3 for each treatment). The primary cultures were then transfected
with a rat CRF-BP-reporter construct containing 3500 base pairs of CRF-BP 5∞ flanking DNA.
Treatment with all five agents produced statistically significant increases above control (P<0.05;
n=3 for each). The results suggest that CRF-BP in the amygdala is stimulated by numerous
pathways which may play a significant role in promoting behavioural changes.
Corticotropin-releasing factor (CRF ) is a neuropeptide which and behavioural responses to stressors (3). CRF neurones
densely innervate the central nucleus of the amygdala andhas been isolated from various species including the sheep,
rat, mouse and human (1). CRF is distributed heterogen- injection of CRF into this region leads to the expression of
numerous stress-like behaviours (4).eously throughout the central nervous system (CNS); it is
also found in placental tissue and other peripheral tissues as The CRF-binding protein (CRF-BP) is a 37-kDa protein
first isolated from human plasma by CRF affinity chromato-well, including the adrenal medulla and testes (2). CRF
co-ordinates the neuroendocrine, behavioural, autonomic and graphy (5) which was subsequently sequenced and cloned.
CRF binds to the CRF-BP with an affinity higher than thatimmune responses to stress (2). There is a body of evidence
which supports an important role for amygdalar CRF in the of the CRF receptor ( Ki=0.4 and 1.7 nM, respectively; 6–8).CRF-BP has been localized to corticotropic cells of themediation of stress-like behaviours. Amygdalofugal pathways
have been documented to participate in autonomic, endocrine anterior pituitary, where it is thought to regulate ACTH
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totally removed at day 5 and replaced by fresh medium containing cytosinesecretion by binding to CRF and inhibiting its ACTH releas-
arabinoside (AraC; 20 mM) to limit the proliferation of glial cells (14).ing activity (9). This has been demonstrated in rat primary
pituitary cultures (8) as well as in cultured mouse anterior Immunocytochemistry
pituitary cells (7). The ABC method using a VectaStain kit (Vector Labs, Burlingame, CA,
USA) was utilized using a rabbit antibody to CRF-BP (provided by W. Vale,It has been hypothesized that CRF-BP levels may modulate
PhD, Salk Institute, La Jolla, CA, USA). Protocols from Vector Labs werethe HPA axis in response to stress. Following restraint stress,
utilised. Tissue was incubated initially with normal goat serum with 2%steady state levels of pituitary CRF-BP mRNA increase 2–3
bovine serum albumin (BSA) for 30 min at room temperature to block non-
times over basal levels of expression for up to 2 h after the specific binding and then incubated with the CRF-BP antibody (152000)
restraint (10). CRF-BP has also been detected in numerous overnight at 4 °C. This was followed by a 30-min incubation at 4 °C with
biotinylated IgG (Vector Laboratories, Burlingame, CA, USA) and then withlimbic regions, including the amygdala (9). Although the
the ABC complex (Vectastain Elite ABC Kit, Vector Labs). The culturesfunction of CRF-BP in the amygdala is not known, CRF-BP
were then incubated with the substrate-diaminobenzidine/H2O2 (DA substrateand CRF are colocalized at the cellular level in the amygdala. Kit, Vector Labs) at room temperature for 2–10 min. Cultures were photo-
It is possible that the CRF-BP may regulate CRF’s actions graphed with a Leitz Ortholux microscope interfaced with a Leica Wild
MPS52 camera.in the amygdala like that in the pituitary.
In this report we seek to further our understanding of the
Stimulation experiments
cellular regulation of CRF-BP expression in the amygdala by
Cells were washed with SFM. Test substances were then added in an
utilising primary amygdalar cultures. Determination of the incubation medium consisting of b-Pit Julip+0.1% BSA, based on Vale et al.
signal transduction pathways responsible for amygdalar (15). For the final CRF-BP mRNA analysis, cultures were incubated for 12 h
and for CRF-BP analysis cultures were incubated for 24 h. The following testCRF-BP expression would help investigators better under-
substances at the following concentrations were utilized: CRF (Peninsulastand what role limbic CRF-BP plays in the mediation of
Laboratories, Inc., Belmont, CT, USA; 1, 10, 100, 1000 nM), forskolinstress behaviours. We have examined the cellular actions of
(Sigma; 0, 1, 3, 10, 30 mM), the phorbol ester-phorbol 12 myristate 13-acetate
CRF on CRF-BP mRNA and protein expression with activ- (TPA; Sigma; 0, 1, 20, 50 nM), interleukin-6 (IL6; Promega, Madison, WI,
ators of the protein kinase A and protein kinase C pathway, USA; 0, 10, 50, 100, 500 pM) and dexamethasone (Sigma; 0, 1, 10, 50,
100 nM ). For mRNA analysis, we initially treated cultures with the highestthe cytokine interleukin-6 and dexamethasone. Since all
dose of each stimuli for 6, 9, 12, 18 or 24 h and then chose the optimal timeagents increased expression, we have also transfected primary
for performing concentration-response studies. Each experiment was replic-
amygdalar cultures with a reporter construct containing 3500 ated at least twice and each experiment was derived from a different
base pairs of the 5∞ regulatory region of the CRF-BP gene preparation of primary cultures.
with the above stimuli in order to determine whether this
CRF-BP mRNA detection by Northern hybridizationgene region accounts for the observed alterations in CRF-BP
Total RNA from cells was isolated using the TRIzol reagent (Researchexpression.
Products International, Cincinnati, OH, USA). Twenty mg total RNA per
lane was electrophoresed in an agarose-formaldehyde gel (1.2%/2.2 M) for
2 h at 80 V as previously described (16). RNA was transferred to a Hybond-N
nylon membrane (Amersham, Arlington Heights, IL, USA; 2 °C overnight at
0.25 mA) and cross-linked to the membrane with a Stratalinker 1800 UVMaterials and methods
crosslinker (Stratagene, La Jolla, CA, USA). The Northern Blot was prehy-
Preparation of primary amygdalar cultures bridized in ExpressHyb hybridization solution (Clonetech, Palo Alto, CA,
USA) for 30 min at 65 °C. A 32P-labelled cDNA probe for CRF-BP wasAmygdalar neuronal culture methods were based on Brouard et al. (11),
generated with a PrimeIt-II oligonucleotide kit (Stratagene). The CRF-BPCratty and Birkle (12) and Kasckow et al. (13). The procedures were
probe was generated using a 500-bp PstI fragment from a pBluescript SKapproved by the University of Cincinnati Animal Use Committee. Pregnant
construct provided by Dr W. Vale (Salk Institute, La Jolla, CA, USA). TheSprague Dawley rats (Harlan, Indianapolis, IN, USA), containing embryonic
blot was then hybridized at 65 °C with 1×106 c.p.m./ml labelled probe inday 19 pups were killed by administration of CO2. The uterus was placed in ExpressHyb hybridization solution for 1 h. After washing, the membrane wasphosphate buffered saline (PBS: NaCl, 137 mM; Na2HPO4, 21 mM; KH2PO4, exposed to Xomatic film ( Kodak, Rochester, NY, USA) for 24–48 h and29 mM; KCl, 1.2 mM; pH 7.3) and the embryos were removed and decapit-
developed. A Foto/Eclipse Imager (Fotodyne Inc., Hartland, WI, USA)ated. Following this, the brain was removed and after slicing away the
interfaced with a Power Macintosh 8100/110 using NIH ImageQuant analysisbrainstem, the remainder of the brain was placed ventral side up. A coronal
software was utilized for densitometric quantification of the mRNA bands.cut was made posterior to the optic chiasm and anterior to the diencephalon
Quantifications were done within the linear range of the film.in order to remove the frontal cortical region. A diagonal cut was then made
along the lateral fissure and the amygdaloid region was separated by gently
CRF-BP determination by Western blotpeeling away the cortex.
Brain slices were placed in PBS. Cells were dissociated for 10–15 min at Cells were lysed in 25 mM Tris buffer (pH 8.8) containing 192 mM glycine,
0.1% SDS, and 0.5 mM phenylmethylsulphonyl fluoride. Eighty mg of the37 °C in 0.25% trypsin containing 75 units/ml of DNAse I in serum-free
medium (SFM) consisting of a mixture of Dulbecco’s modified essential lysate was electrophoresed in a 10% acrylamide gel containing 0.4% SDS and
0.5 M Trizma, pH 8.8 at 100 V for 3 h. Protein was transferred to amedium and Ham’s F-12(151, v/v from Gibco, St Louis, MO, USA)
supplemented with 14 mM glucose, 15 mM NaHCO3, 5 mM Hepes and nitrocellulose membrane (Amersham) overnight at 2 °C and 25 V. The mem-
brane was incubated with rabbit antihuman CRF-BP (1510 000): overnight0.05 U/ml of penicillin-streptomycin (Sigma, Gaithersburg, MD, USA). Cells
were collected by centrifugation (500×g, 5 min), resuspended in SFM supple- at 4¡C. After washing, the membrane was incubated with goat antirabbit
antibody (151000; Vector). The membrane was washed at room temperaturemented with 7.5% foetal calf serum (Atlanta Biologicals, Norcross, GA,
USA). For analysis of CRF-BP peptide and mRNA, cells were plated at a and the immunoreactive protein bands were detected using the enhanced
chemiluminescence ECL kit (Amersham). The membrane was exposed todensity of 3.5 million cells/100 mm tissue culture dishes (Falcon, Franklin
Lakes, NJ, USA). For microscopic analysis, cells were grown in 8-well Lab- Xomatic film ( Kodak) for 2–60 s and then developed. A Foto/Eclipse Imager
(Fotodyne, Inc.), interfaced with a Power Macintosh 8100/110 using NIHTek II Chamber Slide Systems at 75 000 cells per well (Nalge Nunc
International, Naperville, IL, USA). ImageQuant analysis software, was used for densitometric analysis of band
intensity. This was normalized to total protein per lane of loaded lysate.We coated the plates with gelatin (250 mg/ml, 30 min, room temperature;
Sigma) and polyornithine (MW=40 000; 1.5 mg/ml, overnight at room Rainbow markers (Gibco BRL) were used to estimate protein size.
Recombinant CRF-BP(25 pg) served as a positive control (provided bytemperature; Sigma) based on Brouard et al. (11). Following plating, cells
were incubated at 37 °C in a 95% O2/5% CO2 atmosphere. Medium was Dr Vale).
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Transfection
Cells were transfected in six well plates (Falcon, Lincoln Park, NJ, USA)
with a CRF-BP-chloramphenicol acetyltransferase (CAT) plasmid and treated
with the same stimuli utilised above. Cells were transfected at a density of
2×106 using the Lipofectamine Reagent (Gibco-BRL). The 3,500 CRF-BP-
CAT plasmid utilized contained a 3500 base pair SacI fragment of the rat
CRF-BP gene, #3500 base pairs of 5∞ flanking DNA and 66 base pairs of 5∞
untranslated sequences from exon 1. This was linked to the promoterless
reporter plasmid, pGSVOCAT (18). Four mg of 3500 CRF-BP-CAT and 1 mg
of pSV-b-galactosidase control vector (Promega) were diluted in OptiMem
medium with the Lipofectamine reagent (Gibco-BRL) based on the manufac-
turer’s recommended procedures. DNA solution was then added to the cells
and incubated at 37 °C for 2–3 h. Following a 36-h incubation at 37 °C in
serum containing medium, cells were then treated 15 h with either 100 nM
CRF, 30 mM forskolin, 100 pM IL6 or 50 nM TPA or 8 h with 100 nM
dexamethasone in serum free b-pit Julip medium containing 0.1% BSA. After
treatment, cells were lysed using 100 ml of 250 mM Tris pH 8, 0.5% Triton
X-100 and rapidly frozen on dry ice. CAT assay was performed with 80 ml
of cell extract using the Quan-T-CAT assay system (Amersham). The pSV-
b-galactosidase was included to control for differences in transfection efficiency
and b-galactosidase was assayed based on the Promega protocol. Levels of
CAT expression were normalized to b-galactosidase. In addition, as a control
we transfected cells with the promoterless reporter plasmid, pGSVOCAT.
Statistical analysis
The quantitative data obtained were expressed as mean+SEM. Data were
subjected to ANOVA followed by Duncan’s Multiple Range Test using INSTAT
Software (Loyola University Medical Center, Chicago, IL, USA). A P-value
<0.05 was considered sufficient to reject the null hypothesis.
Results
Morphology of amygdalar CRF-BP cells in vitro
Figure 1 illustrates a typical amygdalar culture stained
with anti-CRF-BP antibody 17 days following dispersion.
Figure 1 represents control staining in which the CRF-BP
antibody was replaced by non-immunised rabbit serum. By
this time cells grew as monolayers and many cells developed
long processes extending from the cell bodies to the neigh-
bouring cells. Cell viability at this stage was 97.8+0.5% (n=
4) based on trypan blue exclusion. CRF-BP immunoreactive
(A)
(B)
cells displayed immunoreactive cell bodies, elaborate varicose F. 1. This photograph demonstrates the primary amygdalar cultures
on day 17 stained with () anti-CRF-BP antibody or () non-immunizedcell processes and apparent nuclear sparing.
rabbit serum based on methods outlined in the text. The insert (×800)
in () depicts one of the cells, designated by an arrow in which one can
observe CRF-BP immunoreactivity distributed throughout the cell exceptRegulation of CRF-BP mRNA expression in primary
for the nucleus. Magnification of () and lower power portion ofamygdalar cultures
(), ×110.
The size of the CRF-BP transcript in these cells was 1.85
kilobases as observable in other systems (data not shown; (8, the quantitative changes in levels of CRF-BP mRNA with
increasing concentrations of CRF when corrected to 28S.19)). Figure 2 depicts changes in CRF-BP mRNA following
12 h of treatment with various concentrations of CRF. We Concentrations of CRF at 100 and 1000 nM lead to signific-
ant increases in CRF-BP mRNA expression (P<0.05).initially examined time course changes with 1000 nM CRF
treatment at 6, 9, 12, 18 and 24 h (data not shown). The Changes in CRF-BP mRNA following 12 h treatment with
various concentrations of TPA, IL6, dexamethasone or for-peak CRF-BP mRNA expression following CRF treatment
occurred at 12 h. The same was true when other treatments skolin are depicted in Fig. 3. A representative autoradiogram
is shown at the top of each figure and depicts the CRF-BPwere administered so that this time was chosen to examine
concentration-dependent effects of CRF and the other com- mRNA and 28S changes observable in autoradiograms with
concentrations of the various agents. The lower portion ofpounds. The autoradiograms in the upper portion of Fig. 2
depicts the CRF-BP mRNA and 28S ribosomal RNA(28S) each of the figures reveals the quantitative changes in levels
of CRF-BP mRNA corrected to 28S with increasing concen-changes with CRF concentrations of 0, 1, 10, 100 and
1000 nM. The 28S blots showed no change in signal as a trations of each agent. Concentrations of the following agents
lead to significant increases in CRF-BP mRNA expressionresult of CRF or any subsequent challenge and were used to
correct the CRF-BP Northern blot for differences in RNA (P<0.05): 100 pM IL6, 500 pM IL6, 100 nM DEX, 50 nM
TPA and 30 mM forskolin.loading. The histogram in the lower portion of Fig. 2 reveals
© 1999 Blackwell Science Ltd, Journal of Neuroendocrinology, 11, 959–966
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Response of the rat CRF-BP promoter in primary amygdalar
cultures to stimuli
Primary cultures were transfected with a CRF-BP reporter
construct to determine whether similar patterns of regulation
would be observed between transfection assays and endogen-
ous CRF-BP gene expression. The times of incubation were
chosen based on preliminary experiments (data not shown)
which revealed when maximal increases in expression
occurred. The results from the transfection studies are
depicted in Fig. 5. Transfections with the rat CRF-BP pro-
moter-CAT construct followed by treatment with all 5 agents
produced qualitatively similar results as observed above
(P<0.05, n=3 for all ) suggesting that the DNA sequences
required for regulation by CRF, cAMP, TPA, IL6 and
dexamethasone are contained within the 3500 base pair of
CRF-BP DNA. Transfection of the cultures with a
pGSVOCAT construct lacking the 3500 base pair of 5∞
flanking DNA yielded levels of CAT expression which were
no different from that observed in cells which were not
transfected.
Discussion
Primary amygdalar cultures have been utilised in the past to
analyse the actions of stimuli on CRF expression (13). We
have now used this experimental model to study the regulation
of CRF-BP expression. We first determined that our amygda-
lar cultures express CRF-BP which is detectable by immuno-
cytochemistry, Western blot and Northern blot analysis. In
addition, we have demonstrated that the expression of






























































forskolin, dexamethasone, TPA and interleukin-6 (IL6) can
F. 2. CRF-BP messenger RNA changes in primary cultures at increase expression of CRF-BP mRNA and protein and alsovarious nM concentrations of corticotropin-releasing factor (CRF) fol-
stimulate CRF-BP promoter activity. All stimuli examinedlowing 12 h of incubation. A representative autoradiogram of the
to date increase CRF-BP expression; those which decreaseNorthern blots probed for CRF-BP messenger RNA or 28S ribosomal
RNA(28S) expression with increasing concentrations of CRF is shown CRF-BP expression remain to be determined.
on the upper portion of the figure. The histogram at the lower region of The quantitative changes in CRF-BP message and protein
the figure depicts the densitometric values of each concentration at
levels are statistically significant but not dramatic. The modestvarious time points normalized to untreated controls and corrected for
quantitative increases in CRF-BP mRNA levels observedgel loading. Bars represent mean±SEM (n=3–6). Statistical significance
for each concentration in comparison to control, as determined by may reflect our measurement of steady state CRF-BP levels.
anova, followed by Duncan’s Multiple Range Test is represented by * In addition, there does appear to be a discrepancy with
for P<0.05. The data were pooled from at least three independent regards to the relative increases in CRF-BP mRNA andexperiments.
CRF-BP levels achieved with forskolin vs dexamethasone.
Our Western blots detected higher levels of protein expression
with dexamethasone relative to forskolin; with Northern
blots, the opposite was true. The reason for this is unknownRegulation of CRF-BP expression in primary amygdalar
although relative differences in message or protein stabilitycultures
may be a contributing factor.
We questioned whether the expression of CRF-BP was The behavioural and physiologic relevance of the small
responsive to the same agents which increased CRF-BP changes in mRNA and protein expression we observed remain
mRNA expression. We performed semiquantitative Western to be determined. It is possible that levels of CRF-BP mRNA
analysis of total cellular protein after 24 h treatment with induction achieved with these agents could have been greater
30 mM forskolin, 100 nM dexamethasone, 100 pM IL6, if higher concentrations of stimuli were used in the culture
50 nM TPA or 100 nM CRF. The results are depicted in system. The increases in CRF-BP expression observable in
Fig. 4. The upper portion of Fig. 4 depicts a representative our system were, however, comparable to that reported by
Western blot with the various treatments. The histogram in others following the administration of similar stimuli. For
Fig. 4 reveals the semiquantitative densitometric analysis instance, intraventricular injections of IL6 in rats will signi-
obtained with each treatment. Significant increases were ficantly increase metallothionen-II protein levels to approxi-
mately 120% of baseline (20). In addition, intravenousobservable with all treatments (P<0.05; n=3 for all ).
















































































































































































F. 5. Four mg of 3500 -CAT was transfected into 2×106 cells from
primary amygdalar cultures. Cells were treated with 100 nM dexametha-
sone (DEX ) for 8 h or for 15 h with the other stimuli. Promoter activity
is expressed as percentage of control. Milliunits of CAT have been
normalized to milliunits of b-galactosidase and each bar depicts









































































moterless CAT construct (−promoter). Statistical significance for each
F. 4. Semi-quantitative Western analysis of CRF-BP expression relat- concentration in comparison to control, as determined by ANOVA and
ive to control with a variety of stimuli after 24 h of treatment. The upper Duncan’s Multiple Range test, is represented by * for P<0.05. The data
portion reveals a representative Western blot of CRF-BP after a variety was pooled from three independent experiments.
of treatments at the same concentrations used for semiquantitative
analysis. Bars represent mean±SEM (n=3). Statistical significance for
amygdalar cultures (13) and the current studies reveal thateach concentration in comparison to control, as determined by ANOVA,
these agents can also increase the expression of CRF-BP.followed by Duncan’s Multiple Range Test is represented by * for
P<0.05. The data were pooled from three independent experiments. The net result of such a dual effect would be expected to
alter the bioavailability of CRF.
There is evidence from various model systems that agentsinjections of IL6 in rats result in significant 20% increases in
hippocampal 5-HIAA levels relative to control (21). such as protein kinase activators can modulate CRF-BP
expression. In mixed neuronal and pure astrocyte cultures,Cross talk between various signal transduction pathways
may occur in the amygdala in vivo and this mechanism may activators of protein kinase A (PKA) and PKC will increase
CRF-BP expression (17). Transfection experiments withbe one way in which the small changes in CRF-BP expression
we observed may be amplified with multiple stimuli. For CRF-BP reporter constructs in tumour derived cell lines
demonstrate positive regulation of the CRF-BP promoter byinstance, the STAT5 and glucocorticoid receptor pathways
are known to interact synergistically to enhance casein gene protein kinase A and by CRF in cells expressing the CRF-
receptor (18). In an immortalized amygdalar cell line, CRF,expression (22). Furthermore, STAT5 is known to play a
role in activating the c-fos gene and in this manner, IL-6 and forskolin, IL6, TPA and dexamethasone will also stimulate
CRF-BP expression. The results from our observations inprotein kinase C (PKC ) pathways may also converge (23).
It is also of interest that some agents which increase the dissociated amygdalar cultures are entirely consistent with all
of these findings and furthermore appear to validate theexpression of CRF in amygdalar cultures also increase the
expression of CRF-BP. We had previously demonstrated that immortalized amygdalar cell line as a useful model of
CRF-BP expression (19).forskolin and IL6 will increase CRF expression in dissociated
F. 3 CRF-BP messenger RNA changes in primary cultures at various concentrations of: () phorbol-12-myristate-13-acetate (TPA); () interleukin-6
(IL6); () dexamethasone (DEX ); or ( ) forskolin (FORK) following 12 h of incubation. A representative autoradiogram of the Northern blots
probed for CRF-BP messenger RNA or 28S ribosomal RNA(28S) expression with increasing concentrations of each stimuli is shown on top of each
histogram. The histogram depicts, for each treatment, the densitometric values of each concentration at various time points normalized to untreated
controls and corrected for gel loading. Bars represent mean±SEM (n=3–6). Statistical significance for each concentration in comparison to control,
as determined by ANOVA, followed by Duncan’s Multiple Range Test is represented by * for P<0.05. The data were pooled from at least three
independent experiments.
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In contrast, the responses of CRF and CRF-BP to dexa- (28). To what extent our cell dispersion procedure promotes
a biological situation similar to inflammation or injury ismethasone are distinct in the dissociated amygdalar cultures.
Previously we reported a lack of response of CRF mRNA in unclear.
It is not clear which response elements in the CRF-BPdissociated amygdalar cultures to dexamethasone (13). In
addition, in those experiments, dexamethasone was not able gene could modulate the IL6 response. There are NF-kB sites
in the CRF-BP gene which could facilitate the actions ofto alter the stimulated response of the CRF peptide achieved
with forskolin or IL6. The lack of a CRF response to other interleukins. However, IL6 is known to act via the
JAK/STAT signalling pathway (29). Most of the STATdexamethasone in these amygdalar cultures contrasts with
the consistent decreases of CRF levels demonstrable in the proteins except for STAT6 bind to a consensus sequence
consisting of 5∞-TTCxxxGAA-3∞; for STAT6 the bindinghypothalamus following glucocorticoid treatment (24).
Makino et al. (25) observed both positive and negative element is 5∞-TTCxxxxGAA-3∞ (30). There are no consensus
response elements for any of the STAT proteins in the 700regulation of rat amygdalar CRF mRNA by glucocorticoids
in vivo, dependent on the doses utilized and the time course base pairs 5∞ to the CRF-BP transcript start site. However,
for STAT6, there is one region, i.e. from −481 to −472, inof administration. On the other hand, Beyer et al. (26)
demonstrated that adrenalectomy does not alter the expres- which five out of the six consensus base pairs can be found.
Likewise, for the other STAT binding elements, there are twosion of CRF in the amygdala. Although dexamethasone did
not alter CRF levels in our previous studies with primary regions which contain five out of the required six base pairs.
One of these is located from −201 to −193 and another isamygdalar cultures, we found here that dexamethasone will
alter levels of the CRF-BP intracellularly. This provides a located from −481 to −473. It is possible that these regions
interact with STAT proteins to alter CRF-BP gene expression.potential mechanism by which steroids can regulate CRF
indirectly through actions on its binding protein. Alternatively, consensus STAT binding elements which trans-
duce the actions of IL6 could also be present furtherThe positive regulatory effect of dexamethasone on
CRF-BP in the pituitary is consistent with what we have upstream.
Increased understanding of the mechanisms regulatingobserved in primary amygdalar cultures. In vivo, glucocortico-
ids positively regulate CRF-BP expression in the pituitary CRF-BP expression in the amygdala is important because of
the implied link between CRF expression and CRF-BP as(10). This is based on the finding that adrenalectomy will
decrease rat pituitary CRF-BP expression. Other signal trans- coregulators and their potential role in the behavioural
manifestations of stress. The studies in this report demon-duction pathways regulating CRF-BP expression in the pituit-
ary have not yet been investigated. strate that amygdalar CRF-BP appears to be positively
regulated by a variety of stimuli—the cytokine IL6, activatorsThe rat CRF-BP gene is known to contain CRE and AP-1
sites (18). AP-1 sites have been located at basepairs – 177 to of the PKA and PKC intracellular pathway, dexamethasone
and, more importantly CRF. The elucidation of these signal– 171, −196 to −190 and from −238 to −232. It is likely
that one or more of these sites mediate the TPA effect transduction mechanisms are likely to be important in under-
standing the molecular basis of stress related behaviouralobservable in our studies. Likewise the CRE at −127 to
−123 likely accounts for the forskolin effect in our experi- alterations in the amygdala such as those involving anxiety
or fear and even possibly depressive and anxiety disorders.ments. No consensus glucocorticoid response element (GRE)
sequence is present in the 700 base pairs 5∞ to the CRF-BP
transcript start site. However, a GRE could be present further
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